Cell or Molecular Dysfunction

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

2 weeks ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO

4 weeks ago talkbio0Tagged Andrew Witty, CEO, financial guidance suspension, Leadership Change, personal reasons, Stephen Hemsley, stock drop, Transition Mutation, UnitedHealth Group

UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop

Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25

1 month ago talkbio0Tagged AACR25, Cancer Research, High-Frequency Microsatellite Instability, Inhibitor, Neoplasms, Roche (company), Werner Syndrome

Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology

Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme

2 months ago talkbio0Tagged ALT-positive, Boehringer, cellular targeting, Ingelheim, Malignant Neoplasms

Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting

Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO

3 months ago talkbio0Tagged Abbas Kazimi, Biotechnology, CEO, computational drug discovery, Nimbus, Transition Mutation

Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery

Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026

4 months ago talkbio0Tagged biopharmaceutical company, CEO, Christophe Weber, Drug Industry, Kim, Leadership, succession, Takeda, Transition Mutation

Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company

Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification

5 months ago talkbio0Tagged Alzheimer 's disease, Biogen, diversification, Immunology, Nerve Degeneration, Neuroscience discipline, Research Strategy

Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration

FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

7 months ago talkbio0Tagged Acute leukemia, Approved, Chromosomal translocation, KMT2A gene, Menin Inhibitor, Relapsing course, Revuforj, Syndax, United States Food and Drug Administration, Unresponsive to Treatment

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment

8 months ago talkbio0Tagged Approved, HER2-negative, Hormones, Itovebi, Malignant neoplasm of breast, PI3 K inhibitor, PIK3CA Gene Mutation, receptor-positive, Roche (company), United States Food and Drug Administration

Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

8 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration